Legal
Effective August 2026 · last reviewed September 2026
Peptide America is paid by commission. Certain supplier links carry tracking through Katalys, an affiliate network; when a reader follows one of those links and goes on to start care with that supplier, the supplier pays the network a commission and the network pays this publication a share of it. That is the entire revenue model. Nothing on this site is sold to a reader, and no reader has ever been charged anything by this publication.
A reader pays nothing extra for arriving through a partner link. The commission is paid by the supplier out of its own margin; the price a reader is quoted is the price that supplier quotes anyone, and following a link from here neither raises it nor, unless a supplier says otherwise on its own page, lowers it.
Stated in the form the Federal Trade Commission’s endorsement guidance expects, and repeated here so it is not only in a footer: Peptide America has a material connection to the partner programs linked on this site, in the form of a commission paid on referred business. That connection exists whether or not a reader clicks, and it is disclosed beside every partner link, not only on this page.
Partner links appear in three places, and every one of them is a paid program.
Every partner link is marked as sponsored in the markup, passes through this domain’s /go/ redirector, and sits beside a line that says the reference earns a commission on starts. No supplier is listed without a commercial relationship, so a reader never has to work out which entries in a list pay and which do not.
The header and footer, the molecule index, the glossary, the evidence index and its topic pages, the status overview, and the method, editor, about, contact and legal pages carry no partner link.
No supplier is ever listed for a molecule whose recorded status is pending rulemaking, research-only or withdrawn. Where there is no lawful United States supply route, the monograph presents the regulatory record and the published evidence and names no seller; it does not route the reader to a seller of something that cannot lawfully be dispensed, and it does not offer a substitute in order to have something to sell. The general partner card described above still appears on those pages, and it says nothing about the molecule.
Nor is a body paragraph ever a placement. Partner links do not appear inside monograph prose, inside a regulatory record entry, or inside a citation; the supply section is separated from the record on purpose so that the two are never mistaken for each other.
A commercial relationship does not change a regulatory status, a date, or a citation. Those three are the product, and they are drawn from primary records — FDA labeling and approval documents, the section 503A bulk drug substances lists, advisory committee recommendations, proposed and final rules, published literature — verified on a stated date by the process described on the method page.
A molecule that cannot lawfully be compounded is recorded as such no matter who would profit from a softer word; a date is the date the record was read; a citation points at the document that says the thing, and is not swapped for a friendlier one. If a partner were to ask for a status to be worded more favorably, the answer would be no, and the request would not be recorded as a status change.
No supplier pays for inclusion in this index, for placement within a supply section, for a rating, or for the removal of an unfavorable line. There is no sponsored post, no paid review, no advertorial, and no arrangement under which a payment produces coverage. Inclusion in a supply section requires that the program be approved for this publication’s account, that the molecule be one a reader may lawfully obtain, and that the supplier’s own page shows it offers that molecule; it is not bought, and it cannot be.
The corollary matters as much: a supplier that pays no commission is not excluded from this reference for that reason. The approved product for a molecule is named on the monograph whether or not anyone pays on it, because it is the lawful supply route and leaving it out would misdescribe the record.
Where a supplier’s own public page prints a price for a molecule, the supply section records it with the month it was read; where the page prints none, no price is shown, and none is estimated. A price here is never taken from an affiliate landing page, a promotion or a checkout. Prices, program terms, eligibility criteria, shipping states, formulations and availability all change, often without notice; a supplier may pause intake, drop a molecule, or leave the network between one reading and the next.
Whatever a reader is about to pay or agree to is confirmed at the supplier, on the supplier’s own page, at the moment of the transaction — not from anything recorded here.
Peptide America is an independent reference. It is not a pharmacy, an outsourcing facility, a compounder, a prescriber, or a telehealth service; it holds no relationship with any pharmaceutical manufacturer; and its relationships with suppliers are affiliate agreements and nothing more. Nothing published here is medical advice, and a monograph is not a recommendation to use a compound — see the medical disclaimer.
The way to test this page is to find something wrong and report it. A status that contradicts the primary source, a date that no longer holds, a citation that does not say what it is cited for, a partner link on a page that should carry none, or a disclosure missing where a rail carries one: write to editor@peptideamerica.org, naming the page and, where possible, the source that contradicts it.
Reports are examined against the primary record. Where the report is right the page is corrected and the correction is dated; where it is not, the reasoning and the source are sent back. A correction is never quietly overwritten, because a dated record whose history can be erased is not a record.
Analytics practices and the opt-out are described on the privacy page; the conditions of use are on the terms page.